Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jenny Yang, Pharm D
Gilead Sciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
88 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
CHRU Lille, France
- Facility name not stated
Clichy, France
- Facility name not stated
Créteil, France
- Facility name not stated
La Tronche, France
- Facility name not stated
Lyon, France
- Facility name not stated
Marseille, France
- Facility name not stated
Nice, France
- Facility name not stated
Paris, France
- Facility name not stated
Berlin, Germany
- Facility name not stated
Cologne, Germany
- Facility name not stated
Düsseldorf, Germany
- Facility name not stated
Essen, Germany
- Facility name not stated
Frankfurt, Germany
- Facility name not stated
Freiburg im Breisgau, Germany
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Hanover, Germany
- Facility name not stated
Mainz, Germany
- Facility name not stated
Bologna, Italy
- Facility name not stated
Brescia, Italy
- Facility name not stated
Milan, Italy
- Facility name not stated
Padova, Italy
- Facility name not stated
Palermo, Italy
- Facility name not stated
Roma, Italy
- Facility name not stated
San Giovanni Rotondo, Italy
- Facility name not stated
Torino, Italy
- Facility name not stated
San Juan, Puerto Rico
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Málaga, Spain
- Facility name not stated
Santander, Spain
- Facility name not stated
Seville, Spain
- Facility name not stated
Birmingham, Wstmid, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Manchester, United Kingdom
- Facility name not stated
Plymouth, United Kingdom
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
La Jolla, California, United States
- Facility name not stated
Long Beach, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Palo Alto, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2012
- Primary completion
- 31 Mar 2014
- Completion
- 30 Apr 2014
- Last update posted
- 16 Nov 2018
- Registered enrollment
- 870
- Registry id
- NCT01701401
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.